What do systematic reviews say?

C1 esterase inhibitor vs placebo or active control

C1 esterase inhibitor may leads to lower risk of HAE attacks (during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.29 [0.16, 0.5]
  1 study · 43 participants
  Low

C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Low

C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

C1 esterase inhibitor vs placebo or active control

It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.34 [0.01, 8.14]
  1 study · 44 participants
  Very low

C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Low

C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

C1 esterase inhibitor vs placebo or active control

C1 esterase inhibitor showed no clear difference in adverse events (during compared with placebo or active control (moderate certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.03 [0.84, 1.27]
  1 study · 44 participants
  Moderate

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 344 participants
  Low
• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 108 participants
  Moderate

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 183 participants
  Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 136 participants
  Low
• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 108 participants
  Moderate

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 411 participants
  Very low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 314 participants
  Very low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 410 participants
  Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Discontinuing cholinesterase inhibitor showed no clear difference in dropout due to lack of efficacy of trial medication or deterioration… compared with continued cholinesterase inhibitor (low certainty).

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  OR 1.53 [0.84, 2.76]
  4 studies · 583 participants
  Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Discontinuing cholinesterase inhibitor showed no clear difference in adverse events (any) compared with continued cholinesterase inhibitor (low certainty).

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  OR 0.85 [0.57, 1.27]
  4 studies · 446 participants
  Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Discontinuing cholinesterase inhibitor showed no clear difference in serious adverse events (SAEs) compared with continued cholinesterase inhibitor (low certainty).

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  OR 0.8 [0.46, 1.39]
  4 studies · 390 participants
  Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Discontinuing cholinesterase inhibitor showed no clear difference in deaths compared with continued cholinesterase inhibitor (low certainty).

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  OR 0.75 [0.36, 1.55]
  5 studies · 598 participants
  Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 109 participants
  Moderate

Nanofiltered C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nanofiltered C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low